Physician profile
Hangama Abassi
NPI 1487083655
$3,284.22
in general payments reported to CMS, 2019-2025
29 companies · $1,732 in 2025
The $1,732 reported for 2025 was more than what 92% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $187 · 2023: $670 · 2024: $695 · 2025: $1,732.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,005 · Education: $91.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,004.93 |
| Education | $91.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $269.92 | 2022-2024 | |
| Incyte Corporation | $262.10 | 2023 | Monjuvi |
| Astrazeneca Pharmaceuticals LP | $243.85 | 2024-2025 | Calquence, Enhertu, Imfinzi |
| Merck Sharp & Dohme LLC | $230.42 | 2025 | Keytruda, Lynparza, Keytruda Qlex |
| Janssen Biotech, INC. | $194.73 | 2023-2025 | Darzalex, Tecvayli, Carvykti |
| Novartis Pharmaceuticals Corporation | $184.29 | 2025 | |
| Pfizer INC. | $171.09 | 2025 | |
| Daiichi Sankyo INC. | $166.52 | 2025 | Enhertu, Datroway |
| Takeda Pharmaceuticals U.S.A., INC. | $143.71 | 2024-2025 | Iclusig, Ninlaro |
| Astellas Pharma US INC | $142.19 | 2024-2025 | Xospata, Xtandi |
| E.R. Squibb & Sons, L.L.C. | $134.14 | 2023 | Reblozyl |
| Pharmaessentia USA Corporation | $124.88 | 2023 | Besremi |
| Rigel Pharmaceuticals, INC. | $123.50 | 2023 | Tavalisse, Rezlidhia |
| Genzyme Corporation | $121.63 | 2024 | |
| Boston Scientific Corporation | $121.43 | 2024-2025 | Farapulse, Lux-Dx Insertable Cardiac Monitor |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Legend Biotech USA INC. | $113.09 | 2025 | Carvykti |
| Seagen INC. | $91.99 | 2025 | |
| Cti Biopharma Corp. | $67.38 | 2022 | |
| Lilly USA, LLC | $56.90 | 2025 | Verzenio, Jaypirca |
| Abbvie INC. | $56.38 | 2025 | |
| Celgene Corporation | $52.94 | 2025 | Reblozyl |
| Sobi, INC | $44.52 | 2025 | |
| Servier Pharmaceuticals LLC | $38.80 | 2025 | |
| Exelixis INC. | $30.29 | 2025 | Cabometyx |
| Recordati_rare_diseases_inc. | $21.27 | 2025 | Enjaymo |
| Deciphera Pharmaceuticals INC. | $21.16 | 2025 | Romvimza, Qinlock |
| Gilead Sciences, INC. | $20.41 | 2025 | Trodelvy |
| Adc Therapeutics America, INC. | $18.08 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $16.61 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hangama Abassi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.